Aitia is the leader in the application of Causal AI and Digital Twins to discover the next generation of breakthrough drugs. By leveraging the convergence of multi-omic patient data, high-performance computing, and causal learning and AI, Aitia is revealing the hidden biological mechanisms of disease to create Digital Twins of disease in oncology,neurodegenerative disorders, and immunology. Gemini Digital Twins are being used today to discover novel therapies and accelerate R&D in multiple myeloma, prostate cancer, Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease, with several more in development. Aitia’s partners include seven of the top ten pharmaceutical companies, leading academic research and medical centers, medical societies, leading multi-omic data companies, and patient advocacy groups globally.

Data

Health Data

Aitia

Colin Hill

shahid yatoo

Zena Sfeir Gehchan (She/Her)

So-Youn Shin

Mitchell Rosen

McLaren Gould

Ken Levine

Joe Donahue

Jeanne Latourelle

Jan Berger

QIAN DU

Charles Homan

Bruce Church

The Leadership Team at Aitia spearheads the strategic direction and overall operations of the company. This team comprises top executives who oversee research and early drug development, business growth, precision medicine initiatives, people and culture, marketing, strategic alliances, and engineering. Their collective efforts ensure that Aitia remains at the forefront of applying Causal AI and Digital Twins to revolutionize drug discovery and accelerate the development of therapies for complex diseases.

Leadership Team

Engineering Team

Business Development

Leadership Team

About

Team members

Other teams at Aitia

Engineering Team

Business Development